Our newest episode of Infectious Conversations is a discussion with Dr. Erin Duffy, Chief of Research and Development at CARB-X, a global nonprofit partnership that supports companies developing antibiotics, vaccines, diagnostics, and non-traditional products to address resistant bacterial infections and sepsis. Dr. Duffy explains the problems with the current pipeline for antimicrobial medications and how CARB-X functions to help supply funding to companies that are working to bring the latest innovations to patients. But, she says, push incentives like the direct grant money CARB-X and others provide isn’t enough if there is no market or pull incentives on the other side. An important focus of CARB-X’s research is sepsis, and during Sepsis Awareness Month in September, it’s especially important to raise awareness of the dangers of sepsis and highlight the work being done to better prevent, diagnose, and treat these life-threatening infections. Visit carb-x.org to learn more and join the conversation on social with #SepsisAwarenessMonth.
To leave or reply to comments, please download free Podbean or
To leave or reply to comments,
please download free Podbean App.